<DOC>
	<DOCNO>NCT00203957</DOCNO>
	<brief_summary>The purpose study confirm long term tolerability safety oral 20 40 mg/d dos Istradefylline .</brief_summary>
	<brief_title>Study KW-6002 ( Istradefylline ) Parkinson 's Disease Patients With Motor Response Complications Levodopa</brief_title>
	<detailed_description>This Phase III open-label study , patient Parkinson 's disease ( PD ) complete qualify istradefylline study treat istradefylline period one additional year . Starting dosage istradefylline 40 mg/d maintenance dosage discretion Investigator . The available dos istradefylline 20 40 mg/d . Open-label istradefylline treatment initiate patient satisfy criteria participation . Patients undergo screen baseline evaluation assess eligibility . Screening procedure vary slightly depend upon allocation patient one follow two group : Group A : Patients complete double-blind treatment study 6002-US-0 13 , 6002- US-Ol S 6002-EU-007 immediately prior enter open-label trial may interruption study drug 14 day less . The screening visit patient correspond final visit previous istradefylline study . Group B : Patients previously complete double-blind treatment study 6002-US- 013 , 6002-US-O 18 6002-EU-007 discontinue open-label study 6002-US-007 interruption study drug great 14 day . Screening patient occur Week -2 Day -1 Visits . Visits occur ON state procedure conduct order specify , whenever possible . Safety outcome assess physical examination ( include neurological examination ) , clinical laboratory test 12-lead electrocardiogram ( ECG ) screen select subsequent schedule visit . Vital sign , include weight , concomitant medication , adverse event monitor regularly throughout trial . Changes anti-parkinsonian medication permit Investigator 's discretion .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Istradefylline</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Patients complete doubleblind treatment study 6002US0 13 , 6002US0 18 6002EU007 , discontinue openlabel study 6002US007 . Patients female must nonpregnant nonnursing . Women Child Bearing Potential ( WOCBP ) must use reliable method contraception ( e.g. , oral contraceptive longterm injectable implantable hormonal contraceptive , double bather method , condom diaphragm , condom foam , condom sponge intrauterine device ) negative serum ( North American site ) urine ( nonNorth American site ) pregnancy test screen baseline . Women consider childbearing potential surgically sterilize . Patients able give write informed consent Group B Patients treat within 30 day baseline ( five halflives compound , long ) investigational agent istradefylline Patients history psychotic illness . Patients treat within three month ( six month patient treat depot ) baseline trial antipsychotic agent . Patients treat centrally acting drug know dopamine antagonist property therapeutic dos ( e.g. , buspirone , amoxapine ) . Patients atypical parkinsonism . Patients secondary parkinsonism variant . Patients diagnosis cancer evidence continue malignancy within five year study enrollment ( except patient basal cell carcinoma carcinoma situ cervix surgically excise ) . Patients clinically significant illness organ system may compromise safety patient trial affect ability patient complete trial . Patients , reason , judge Investigator inappropriate trial , include patient unable communicate cooperate Investigator . Patients ALT and/or AST level great 1.5 ULN screen ineligible participate trial . Patients history drug alcohol abuse dependence within last year ( DSMIVR ) . Patients significant drug allergy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Parkinson 's Disease</keyword>
</DOC>